Literature DB >> 19337693

Fractionated stereotactic radiation therapy in the management of primary optic nerve sheath meningiomas.

Stefanie Milker-Zabel1, Peter Huber, Wolfgang Schlegel, Jürgen Debus, Angelika Zabel-du Bois.   

Abstract

We analysed our long-term results after fractionated stereotactic radiotherapy (FSRT) in patients with primary optic nerve sheath (pONSM) meningioma, as a rare subtype of meningiomas. Between 01/1995 and 12/2007, 32 patients with pONSM were treated with FSRT. Fifteen patients received radiotherapy as primary treatment, four after biopsy, and six patients after surgical resection. Seven patients were irradiated for recurrent disease. Seventeen lesions were histologically proven and determined as WHO grade I pONSM. Median target volume was 15.7 cc, median total dose 54.9 Gy. Twenty-nine patients showed clinical symptoms before radiotherapy like reduced vision, unilateral loss of vision, or an exophthalmia. Median follow-up was 4.5 years. Overall local tumor control was 100%. Twenty-six patients had stable disease based on CT/MRI, while 6/32 had a partial remission of tumor volume. 97% of our patients showed stable vision or an improvement of visual acuity. Eleven patients (38%) showed an improvement of pre-existing clinical symptoms like double vision, exophthalmia and visual acuity. Only one patient showed an impairment of vision with progressive concentric decreasing of the visual field on the side of the irradiated ONSM. These data demonstrate that FSRT is an effective and safe treatment modality for local control in patients with pONSM with minimal risk of significant late toxicity.

Entities:  

Mesh:

Year:  2009        PMID: 19337693     DOI: 10.1007/s11060-009-9874-8

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  27 in total

1.  Comparison of advanced irradiation techniques with photons for benign intracranial tumours.

Authors:  L Cozzi; A Clivio; G Bauman; S Cora; G Nicolini; R Pellegrini; E Vanetti; S Yartsev; A Fogliata
Journal:  Radiother Oncol       Date:  2006-08-04       Impact factor: 6.280

2.  Optic nerve sheath meningioma: diagnostic features and therapeutic alternatives.

Authors:  N J Sarkies
Journal:  Eye (Lond)       Date:  1987       Impact factor: 3.775

3.  Microsurgical removal of a primary intraorbital meningioma.

Authors:  L E Mark; J S Kennerdell; J C Maroon; A E Rosenbaum; R Heinz; B L Johnson
Journal:  Am J Ophthalmol       Date:  1978-11       Impact factor: 5.258

4.  Treatment accuracy of fractionated stereotactic radiotherapy.

Authors:  Shaleen Kumar; Kevin Burke; Colin Nalder; Paula Jarrett; Cephas Mubata; Roger A'hern; Mandy Humphreys; Margaret Bidmead; Michael Brada
Journal:  Radiother Oncol       Date:  2005-01       Impact factor: 6.280

Review 5.  Radiation therapy in the multimodal treatment approach of pituitary adenoma.

Authors:  Gerd Becker; Martin Kocher; Rolf-Dieter Kortmann; Frank Paulsen; Branislav Jeremic; Rolf-Peter Müller; Michael Bamberg
Journal:  Strahlenther Onkol       Date:  2002-04       Impact factor: 3.621

6.  Preliminary visual outcomes after three-dimensional conformal radiation therapy for optic nerve sheath meningioma.

Authors:  Samir Narayan; Wayne T Cornblath; Howard M Sandler; Victor Elner; James A Hayman
Journal:  Int J Radiat Oncol Biol Phys       Date:  2003-06-01       Impact factor: 7.038

7.  [Improved patient repositioning accuracy by integrating an additional jaw fixation into a high precision face mask system in stereotactic radiotherapy of the head].

Authors:  Eric Lopatta; Susie-Maria Liesenfeld; Priska Bank; Reinhard Wurm; Robert Günther; Tilo Wiezorek; Thomas G Wendt
Journal:  Strahlenther Onkol       Date:  2003-08       Impact factor: 3.621

8.  The management of optic nerve sheath meningiomas.

Authors:  J S Kennerdell; J C Maroon; M Malton; F A Warren
Journal:  Am J Ophthalmol       Date:  1988-10-15       Impact factor: 5.258

9.  Improved target volume definition for fractionated stereotactic radiotherapy in patients with intracranial meningiomas by correlation of CT, MRI, and [68Ga]-DOTATOC-PET.

Authors:  Stefanie Milker-Zabel; Angelika Zabel-du Bois; Marcus Henze; Peter Huber; Daniela Schulz-Ertner; Angelika Hoess; Uwe Haberkorn; Jürgen Debus
Journal:  Int J Radiat Oncol Biol Phys       Date:  2006-02-20       Impact factor: 7.038

Review 10.  Primary optic nerve sheath meningioma: stereotactic fractionated radiation therapy as an emerging treatment of choice.

Authors:  Branislav Jeremic; Susanne Pitz
Journal:  Cancer       Date:  2007-08-15       Impact factor: 6.860

View more
  6 in total

1.  Primary and Secondary Optic Nerve Sheath Meningioma.

Authors:  Elena Solli; Roger E Turbin
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-18

2.  Endocrine and visual function after fractionated stereotactic radiotherapy of perioptic tumors.

Authors:  M Kocher; H Treuer; M Hoevels; R Semrau; V Sturm; R-P Mueller
Journal:  Strahlenther Onkol       Date:  2012-12-20       Impact factor: 3.621

3.  Hypofractionated stereotactic radiotherapy (HFSRT) for who grade I anterior clinoid meningiomas (ACM).

Authors:  Selcuk Demiral; Ferrat Dincoglan; Omer Sager; Hakan Gamsiz; Bora Uysal; Esin Gundem; Yelda Elcim; Bahar Dirican; Murat Beyzadeoglu
Journal:  Jpn J Radiol       Date:  2016-09-22       Impact factor: 2.374

4.  Prior surgical intervention and tumor size impact clinical outcome after precision radiotherapy for the treatment of optic nerve sheath meningiomas (ONSM).

Authors:  Sebastian Adeberg; Thomas Welzel; Stefan Rieken; Jürgen Debus; Stephanie E Combs
Journal:  Radiat Oncol       Date:  2011-09-18       Impact factor: 3.481

Review 5.  Optic nerve sheath meningiomas: prevalence, impact, and management strategies.

Authors:  Richard T Parker; Christopher A Ovens; Clare L Fraser; Chameen Samarawickrama
Journal:  Eye Brain       Date:  2018-10-24

6.  Long-Term Visual Function After Fractionated Stereotactic Radiotherapy for Primary Optic Nerve Sheath Meningioma: A Retrospective Analysis of 34 Subjects.

Authors:  Kavin Vanikieti; Chaloemwong Chaiwithooanukul; Putipun Puataweepong; Panitha Jindahra; Tanyatuth Padungkiatsagul
Journal:  Clin Ophthalmol       Date:  2022-09-22
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.